Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lync-101

Phase 1

LLyncBio Therapeutics Co., Ltd.

Lync-101 is one of 2 therapeutic programs targeting UC - Ulcerative Colitis. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

UC - Ulcerative ColitisEnrolling by invitation

UC - Ulcerative ColitisPhase 1

Enrolling by invitation

Competition

Competitive Landscape

2 competitors in UC - Ulcerative Colitis

#DrugCompanyPhaseTrials

D-2570

IInventisBio Co., Ltd

Lync-101

LLyncBio Therapeutics Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

UC - Ulcerative Colitis1 trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

Enrolling by invitation·LLyncBio Therapeutics Co., Ltd.·Phase 1·NCT07505030·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lync-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lync-101. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — LyncBio Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: LLyncBio Therapeutics Co., Ltd.

Related News